Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population

Basit Öğe Kaydı
dc.authoridElkıran, Emin Tamer/0000-0001-6681-7249
dc.authoridSevinç, Alper/0000-0002-0499-8918
dc.authoridbenekli, mustafa/0000-0003-3184-4946
dc.authoridÖksüzoğlu Çakmak, Ömür Berna/0000-0002-2756-8646
dc.authorwosidElkıran, Emin Tamer/ABI-8192-2020
dc.authorwosidSevinç, Alper/KPA-4519-2024
dc.authorwosidCoşkun, Hasan Şenol/C-2070-2016
dc.authorwosidÖzet, ahmet/ABC-9831-2021
dc.authorwosidbenekli, mustafa/AAE-4555-2020
dc.authorwosidSevinc, Alper/KFQ-6440-2024
dc.authorwosidYalcin, Suayib/KWT-7106-2024
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorYalcin, Suayib
dc.contributor.authorOzkan, Metin
dc.contributor.authorElkiran, Emin Tamer
dc.contributor.authorSevinc, Alper
dc.contributor.authorCabuk, Devrim
dc.contributor.authorCoskun, Hasan Senol
dc.date.accessioned2024-08-04T20:58:38Z
dc.date.available2024-08-04T20:58:38Z
dc.date.issued2015
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib is used in Turkey with special permission by the Ministry of Health for this indication. Patients and methods: Patients with advanced DTC and MTC were retrospectively identified from the Turkish Ministry of Health database. Data on these patients were prospectively collected before permission is granted to use sorafenib. Results: Thirty patients with complete data were analyzed: 14 DTC (papillary number [n] = 10; follicular n=4) and 16 MTC. The median age of the patients was 57 years (range: 28-79 years), and there were 18 males and 12 females. All DTC patients were iodine refractory and had received a median three doses of radioactive iodine (range: 1-7 doses). Sorafenib was used for a median of 12 months (range: 1-49 months). The overall response rate was 20%, all partial responses, with no complete response. The overall response rate was 14% in DTC and 25% in MTC patients. The median progression-free survival (PFS) was 17.1 months (95% confidence interval [CI]: 7.3-26.8) and overall survival (OS) was not reached. The 2-year PFS and OS were 39% and 68%, respectively. DTC and MTC patients had similar survival outcomes: median PFS of 21.3 months (95% CI: 5.8-36.7) versus 14.5 months (95% CI: 3.7-25.2), respectively (P=0.36), with the median OS not reached in either group (P=0.17). Tumor marker levels did not have any prognostic or predictive role. The toxicity profile was similar to that of other sorafenib trials. Conclusion: Sorafenib is an effective and well-tolerated treatment in advanced thyroid cancers.en_US
dc.identifier.doi10.2147/OTT.S70670
dc.identifier.endpage5en_US
dc.identifier.issn1178-6930
dc.identifier.pmid25548522en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.2147/OTT.S70670
dc.identifier.urihttps://hdl.handle.net/11616/103028
dc.identifier.volume8en_US
dc.identifier.wosWOS:000346410300001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherDove Medical Press Ltden_US
dc.relation.ispartofOncotargets and Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectadvanced thyroid canceren_US
dc.subjectsorafeniben_US
dc.subjectoverall survivalen_US
dc.titleEfficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish populationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu